Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• This change does not impact other access efforts, including direct-to-patient, self-pay prices

  80% confidence

• With the supply of all doses of these medicines fully available nationwide in the US, there is no reason for patients to gamble with their health with knock-off products produced by compounders

  80% confidence

• Not all GLP-1s are the same. Semaglutide offers powerful efficacy and, unlike any other molecule in the GLP-1 class, it has FDA-approved medicines with a broad range of indications

  80% confidence

• The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs

  80% confidence

• Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States

  80% confidence

Data points we hold from this source